甲状旁腺功能亢进症 中国就医指南

Hyperparathyroidism is an endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH) from one or more of the four parathyroid glands, leading to dysregulated calcium and phosphorus metabolism. It is broadly classified into primary, secondary, and tertiary forms. Primary hyperparathyroidism (PHPT), the most common type, results from autonomous PTH overproduction—typically due to a single parathyroid adenoma (85–90%), less commonly hyperplasia (10–15%), or rarely carcinoma (<1%). Secondary hyperparathyroidism arises as a compensatory response to chronic hypocalcemia, most often driven by chronic kidney disease (CKD) or vitamin D deficiency. Tertiary hyperparathyroidism occurs when long-standing secondary disease leads to irreversible parathyroid gland autonomy, frequently seen in advanced CKD patients post-kidney transplant. Pathophysiologically, elevated PTH increases bone resorption, renal calcium reabsorption, and intestinal calcium absorption (via upregulation of renal 1α-hydroxylase and subsequent calcitriol synthesis), resulting in hypercalcemia, hypophosphatemia, and increased urinary calcium excretion. Epidemiologically, PHPT affects approximately 0.1–0.3% of the general population, with incidence rising sharply after age 50; women are affected two to three times more often than men. Risk factors include prior neck irradiation, genetic syndromes (e.g., MEN1, MEN2A, HRPT2 mutations), lithium therapy, and chronic kidney disease. Untreated or severe cases significantly impair quality of life: patients commonly report debilitating fatigue, cognitive fog, depression, muscle weakness, bone pain, recurrent nephrolithiasis, and gastrointestinal disturbances such as constipation and peptic ulcer disease. Osteoporosis and vertebral fractures increase fracture risk by 2–4 fold; cardiovascular complications—including hypertension, left ventricular hypertrophy, and vascular calcification—are also prevalent. Early diagnosis remains challenging, as up to 80% of newly diagnosed cases in high-resource settings are asymptomatic or minimally symptomatic, identified incidentally via routine serum calcium testing. Delayed management may lead to irreversible renal damage (nephrocalcinosis, chronic kidney disease progression) and skeletal demineralization. Importantly, even mild hypercalcemia correlates with measurable declines in physical functioning, sleep quality, and emotional well-being—underscoring the need for individualized assessment beyond biochemical thresholds alone.

# 甲状旁腺功能亢进症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用于轻症（无症状型、血钙＜2.65 mmol/L）、老年高风险患者或术前临时控制：

• •药物治疗：西那卡塞（起始剂量25–50 mg/d）+ 活性维生素D类似物（骨化三醇0.25–0.5 μg/d）；

• •监测与检验：PTH、血钙、磷、25(OH)D、肾功能、骨密度（DXA）等，单次检查费860–1350元；
• •营养干预与随访：限钙限磷饮食指导+每3个月门诊随访，年均管理费1200–2400元。

二、手术治疗方案

适用于原发性甲旁亢确诊（PTH↑+高钙血症）、有骨病/肾结石/肾功能下降者：

• •微创甲状旁腺切除术（MIP）：术前99mTc-MIBI显像（2200–3500元）+ 术中PTH快速检测（800元），手术费+麻醉+住院（5–7天）：28,000–42,000元；
• •双侧颈部探查术：适用于多腺体增生或影像阴性者，费用35,000–52,000元。

三、特殊复杂情况处理

继发性/三发性甲旁亢合并终末期肾病、术后持续高钙或复发者：

• •再次手术（含术中超声+神经监测）：45,000–72,000元；
• •射频消融（超声引导下）：18,000–26,000元（限单枚腺瘤且无法耐受手术者）。

四、方案快速选择指南

• •预算有限/无症状者：首选保守治疗（年支出约3000–9000元）；
• •中青年/有并发症者：推荐MIP手术（性价比最优，根治率＞95%）；
• •透析患者/多次复发者：需多学科会诊，优先考虑再次手术或射频消融。